IM­brave150: Roche’s reg­u­la­to­ry crew plans a glob­al roll­out of Tecen­triq com­bo for liv­er can­cer as PhI­II scores a hit

Just weeks af­ter Bris­tol-My­ers Squibb de­fend­ed its failed piv­otal study pit­ting Op­di­vo against Nex­avar in liv­er can­cer, Roche says it’s beat the front­line chal­lenge with a com­bi­na­tion of their PD-L1 Tecen­triq with Avastin. And now they’re rolling their reg­u­la­to­ry teams in the US, Eu­rope and Chi­na in search of a new ap­proval — bad­ly need­ed to boost a trail­ing fran­chise ef­fort.

Giv­en their break­through and Big Phar­ma sta­tus as well as the use of two ap­proved drugs, FDA ap­proval may well prove to be some­thing of a for­mal­i­ty. And the Chi­nese have been clear that they want new drugs for liv­er can­cer, where lethal dis­ease rates are par­tic­u­lar­ly high.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER